CN113387847B - Synthetic method of magnesium taurate - Google Patents
Synthetic method of magnesium taurate Download PDFInfo
- Publication number
- CN113387847B CN113387847B CN202110702332.4A CN202110702332A CN113387847B CN 113387847 B CN113387847 B CN 113387847B CN 202110702332 A CN202110702332 A CN 202110702332A CN 113387847 B CN113387847 B CN 113387847B
- Authority
- CN
- China
- Prior art keywords
- magnesium
- filtrate
- taurine
- solid
- taurate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/42—Separation; Purification; Stabilisation; Use of additives
- C07C303/44—Separation; Purification
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention discloses a synthetic method of magnesium taurate, and relates to the technical field of health-care food. The method for synthesizing the magnesium taurate comprises the following steps: (1) Keeping the temperature of water at 65-75 ℃, adding taurine while stirring, adding magnesium oxide, stirring for a period of time to obtain a mixed solution A, cooling the mixed solution A, and continuously stirring to obtain a mixed solution B; (2) Filtering or centrifuging the mixed solution B obtained in the step (1) to obtain a filtrate I and a solid I, cooling the obtained filtrate I, and filtering or centrifuging to obtain a filtrate II and a solid II; (3) Evaporating and concentrating the filtrate II obtained in the step (2) to obtain a concentrated solution, continuously stirring, and filtering or centrifuging to obtain a filtrate III and a solid III; (4) And (4) washing and drying the solid III obtained in the step (3) to obtain the magnesium taurate. The application provides a synthetic method of magnesium taurate with high separation purity without organic solvent.
Description
Technical Field
The invention relates to the technical field of health-care food, in particular to a method for synthesizing magnesium taurate.
Background
At present, the main method for synthesizing magnesium taurate is to mix taurine and magnesium oxide (or magnesium hydroxide, etc.) in a ratio of 2:1, reacting in water phase, adding organic solvent such as methanol to precipitate magnesium taurate. The prior art has the following defects: (1) 2:1 mol ratio of taurine to magnesium oxide, wherein the magnesium oxide is difficult to completely react; (2) The solution system obtained after the reaction is a mixture of magnesium taurate and taurine, is not easy to separate and is difficult to obtain a product with higher purity; (3) organic solvents are required; (4) Magnesium taurate solution systems are susceptible to hydrolysis under certain conditions to produce magnesium hydroxide. Magnesium taurate molecular formula Mg [ H ] 2 NC 2 H 4 SO 3 ] 2 The typical equation for the reaction of taurine with magnesium oxide is as follows:
2H 2 NC 2 H 4 SO 3 H+MgO＝＝Mg[H 2 NC 2 H 4 SO 3 ] 2 +H 2 O
disclosure of Invention
Based on the above, the invention aims to overcome the defects of the prior art and provide a method for synthesizing magnesium taurate with high separation purity without organic solvent.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows: a method for synthesizing magnesium taurate comprises the following steps:
(1) Keeping the temperature of water at 65-75 ℃, adding taurine while stirring, adding a magnesium compound, stirring for a period of time to obtain a mixed solution A, cooling the mixed solution A, and continuously stirring to obtain a mixed solution B;
(2) Filtering or centrifuging the mixed solution B obtained in the step (1) to obtain a filtrate I and a solid I, cooling the obtained filtrate I, and filtering or centrifuging to obtain a filtrate II and a solid II;
(3) Evaporating and concentrating the filtrate II obtained in the step (2) to obtain a concentrated solution, continuously stirring, and filtering or centrifuging to obtain a filtrate III and a solid III;
(4) And (4) washing and drying the solid III obtained in the step (3) to obtain the magnesium taurate.
The method ingeniously utilizes the characteristics of taurine and magnesium taurate on solubility, and the purposes of separation and purification are designed and achieved. The solubility of the taurine is high at high temperature and rapidly reduced at low temperature, while the solubility of the magnesium taurate is relatively small along with the change of the temperature, and the existence of the magnesium taurate can make the freezing point of the solution lower than zero, thereby further reducing the solubility of the taurine.
Preferably, in the step (1), the mass ratio of the water, taurine and magnesium compounds is as follows: water: taurine: magnesium compound =13 to 16. Preferably, the magnesium compound is at least one of magnesium oxide, magnesium hydroxide and magnesium carbonate. Further preferably, the compound of magnesium is magnesium oxide.
The application mainly prepares the magnesium taurate by mixing water, taurine and magnesium compounds, wherein the mass ratio of the water, the taurine and the magnesium hydroxide is as follows: water: taurine: magnesium hydroxide =13 to 16; the mass ratio of water, taurine and magnesium carbonate is as follows: water: taurine: magnesium hydroxide =13 to 16.
Preferably, in the step (1), the mass ratio of the water, the taurine and the magnesium oxide is as follows: water: taurine: magnesium oxide =13 to 16. The ratio of taurine to magnesium oxide selected by the application is based on that the magnesium oxide can be completely reacted only when the taurine and the magnesium oxide reach the ratio stated by the application; the amount of water selected in the application is the saturated concentration of taurine and magnesium taurate; if the water content is too low, the generated magnesium taurate will exceed the saturation concentration, which is not beneficial to the reaction and the subsequent separation steps; too much water is not necessary, increasing the difficulty of the subsequent concentration step.
Preferably, in the step (1), the mass ratio of the water to the taurine to the magnesium oxide is as follows: water: taurine: magnesium oxide = 13. The inventors have found, through extensive studies, that the reaction solution obtained at the above ratio is close to a saturated solution of magnesium taurate.
Preferably, in the step (1), the mixture A is obtained after stirring for 30-40 min, the temperature is reduced to 4-6 ℃, and the mixture B is obtained after stirring for 2-4 h. Under the feeding proportion, the reaction temperature and the time adopted by the application, the reaction completion degree and the hydrolysis side reaction of magnesium taurate are mainly considered, and under the condition, the reaction degree of magnesium oxide can be greatly improved. In this step, taurine is in excess and needs to be separated and removed; the solubility of the taurine is greatly changed along with the temperature, and the excessive taurine can be greatly separated out at low temperature, namely solid I; magnesium taurate does not substantially precipitate under the conditions designed by the scheme of the application.
Preferably, in the step (2), the temperature is reduced to-1 to-3 ℃, the mixture is kept stand for 24 to 48 hours or the liquid is placed in a stirrer and stirred for 4 to 10 hours at a constant temperature of-3 ℃. At this time, the filtrate I still contains a certain amount of taurine (for example, 2.5%), and the temperature is reduced to-1 to-3 ℃ so that the taurine can be further precipitated. Practice shows that magnesium taurate is still not obviously precipitated in the step, so that solid II in the following step is still mainly taurine.
Preferably, in the step (3), the mass ratio of the concentrated solution to the filtrate II is: concentrating the solution: filtrate II = 35-45; the temperature of evaporation concentration is 1-3 ℃, and the stirring time is 2-4 h; the concentration by evaporation should be carried out under vacuum or under nitrogen-filled conditions, with the aim of sequestering carbon dioxide. The concentration of taurine in the filtrate II is further reduced (for example, 0.5%), at this time, the concentration of magnesium taurate is close to or reaches the saturated concentration, and the concentration by evaporation is carried out to a certain extent at 1-3 ℃ to precipitate magnesium taurate, while taurine in the filtrate II is not precipitated or is precipitated very little (does not reach the saturated concentration).
Preferably, in the step (4), the temperature of the washing water is 0-1 ℃, and the temperature of the drying is 2-6 ℃. In the application, the mixed liquid of the solid I-taurine, the solid II-taurine, the filtrate III-taurine and a small amount of taurine can be repeatedly used.
In addition, the invention provides magnesium taurate prepared by the synthesis method of the magnesium taurate.
Further, the invention provides application of the magnesium taurate in preparing medicines for treating cardiovascular diseases, iron-deficiency anemia, fever and pain relief, migraine and diabetes.
Compared with the prior art, the invention has the beneficial effects that: (1) The reaction degree of the magnesium compound is improved by proper feeding proportion, reaction temperature and time; (2) organic solvents are not necessary; (3) obtaining a sample with higher purity; and (4) the intermediate material can be recycled without discharge.
Detailed Description
To better illustrate the objects, aspects and advantages of the present invention, the present invention will be further described with reference to specific examples.
Example 1
In an embodiment of the present application, the method for synthesizing magnesium taurate includes the following steps:
(1) Keeping the temperature of water at 65 ℃, adding taurine while stirring, and then adding magnesium oxide, wherein the mass ratio of the water to the taurine to the magnesium oxide is as follows: water: taurine: magnesium oxide =13, stirring for 40min to obtain a mixed solution a, cooling the mixed solution a to 4 ℃, and continuously stirring for 4h to obtain a mixed solution B;
(2) Filtering or centrifuging the mixed solution B obtained in the step (1) to obtain a filtrate I and a solid I, cooling the obtained filtrate I to-1 ℃, and filtering or centrifuging to obtain a filtrate II and a solid II;
(3) Evaporating and concentrating the filtrate II obtained in the step (2) to obtain a concentrated solution, wherein the mass ratio of the concentrated solution to the filtrate II is as follows: concentrating the solution: filtrate II =35, the temperature of evaporation concentration is 1 ℃, stirring is continued for 4h, and filtration or centrifugation is carried out to obtain filtrate III and solid III;
(4) And (4) washing the solid III obtained in the step (3), wherein the temperature of washing water is 1 ℃, and drying is carried out at the temperature of 2 ℃ to obtain the magnesium taurate.
Example 2
In an embodiment of the present application, the method for synthesizing magnesium taurate includes the following steps:
(1) Keeping the temperature of water at 75 ℃, adding taurine while stirring, and then adding magnesium oxide, wherein the mass ratio of the water to the taurine to the magnesium oxide is as follows: water: taurine: magnesium oxide =16, stirring for 30min to obtain a mixed solution a, cooling the mixed solution a to 6 ℃, and continuously stirring for 2h to obtain a mixed solution B;
(2) Filtering or centrifuging the mixed solution B obtained in the step (1) to obtain a filtrate I and a solid I, cooling the obtained filtrate I to-3 ℃, and filtering or centrifuging to obtain a filtrate II and a solid II;
(3) Evaporating and concentrating the filtrate II obtained in the step (2) to obtain a concentrated solution, wherein the mass ratio of the concentrated solution to the filtrate II is as follows: concentrating the solution: filtrate II =45, the temperature for evaporation concentration is 3 ℃, stirring is continuously carried out for 2h, and filtration or centrifugation is carried out to obtain filtrate III and solid III;
(4) And (4) washing the solid III obtained in the step (3), wherein the temperature of washing water is 0 ℃, and drying at the temperature of 6 ℃ to obtain the magnesium taurate.
Example 3
In an embodiment of the present application, the method for synthesizing magnesium taurate includes the following steps:
(1) Keeping the temperature of water at 70 ℃, adding taurine while stirring, and then adding magnesium oxide, wherein the mass ratio of the water to the taurine to the magnesium oxide is as follows: water: taurine: magnesium oxide =15, stirring for 30min to obtain a mixed solution a, cooling the mixed solution a to 4 ℃, and continuously stirring for 4h to obtain a mixed solution B;
(2) Filtering or centrifuging the mixed solution B obtained in the step (1) to obtain a filtrate I and a solid I, cooling the obtained filtrate I to-1 ℃, and filtering or centrifuging to obtain a filtrate II and a solid II;
(3) Evaporating and concentrating the filtrate II obtained in the step (2) to obtain a concentrated solution, wherein the mass ratio of the concentrated solution to the filtrate II is as follows: concentrating the solution: filtrate II =40, the temperature for evaporation concentration is 1 ℃, stirring is continuously carried out for 2h, and filtration or centrifugation is carried out to obtain filtrate III and solid III;
(4) And (4) washing the solid III obtained in the step (3), wherein the temperature of washing water is 1 ℃, and drying is carried out at the temperature of 6 ℃ to obtain the magnesium taurate.
The embodiment of the application only provides a method for synthesizing magnesium taurate by mixing water, taurine and magnesium oxide, and magnesium taurate can be obtained by mixing magnesium hydroxide and magnesium carbonate only in different proportions from the magnesium taurate per se, which is not described in detail herein.
Meanwhile, the application is provided with comparative examples, and the specific comparative examples are as follows:
the preparation method of the comparative example 1 is completely the same as that of the example 1, and only in the step (1), the mass ratio of the water, the taurine and the magnesium oxide is as follows: water: taurine: magnesium oxide =13:2.82:0.45 of the total weight of the mixture;
the preparation method of the comparative example 2 is completely the same as that of the example 1, and only in the step (1), the mass ratio of the water to the taurine to the magnesium oxide is as follows: water: taurine: magnesium oxide = 13;
comparative example 3 is completely the same as the preparation method of example 1, and only in the step (1), the mass ratio of water, taurine and magnesium oxide is as follows: water: taurine: magnesium oxide = 23;
comparative example 4 was completely the same as the preparation method of example 1, and only in step (2), the temperature was lowered to 2 ℃;
comparative example 5 the same procedure as in example 1 was followed except that in step (3), the temperature for the evaporative concentration was 20 ℃;
test example 1
The test process comprises the following steps: respectively detecting the solid I and the filtrate I in the step (2); there are two methods for measuring the magnesium content, and generally, when the magnesium content is too low (the content is only a few thousandths), the ICP method is adopted to measure the magnesium content; generally, the magnesium content is measured by EDTA titration; the "solid I" in examples 1, 2 and 3 was measured by the "ICP method", and the magnesium in the remaining samples was measured by the "titration method"; the taurine detection method adopts a nitrogen determination method.
And (3) test results: as shown in table 1:
TABLE 1 test results
| Example 1 | Comparative example 1 | Comparative example 2 | Comparative example 3 | |
| Solid I Mass (g) | 655 | 198 | 1225 | 568 |
| Solid I magnesium content (%) | 0.144 | 9.13 | 0.14 | 0.08 |
| Solid I taurine content (%) | 88.7 | 76.1 | 87.9 | 90.5 |
| Filtrate I Mass (g) | 1500 | 1380 | 1450 | 2570 |
| Filtrate I magnesium content (%) | 1.70 | 0.60 | 1.71 | 1.01 |
| Filtrate I taurine content (%) | 19.72 | 9.13 | 19.83 | 14.21 |
Note that: the magnesium taurate is 8.82% magnesium per magnesium taurate formula, so for the filtrate, knowing the magnesium content allows calculation of the magnesium taurate content, and for simplicity of presentation, only the magnesium content will be described herein (the same below).
As can be seen from Table 1, in comparative example 1, the magnesium content in "solid I" is higher and the magnesium content in "filtrate I" is lower than that in example 1, and it can be seen that in comparative example 1, the reaction degree of magnesium oxide is obviously lower, which means that the dosage ratio of taurine to magnesium oxide should not be too low; compared with example 1, comparative example 2 has no obvious difference in other aspects except that the mass of the solid I is increased, and the stirring difficulty during the reaction is increased when the amount of the taurine is greatly increased (the solid content is too large) because the amount of the water is fixed, so that it is not necessary to set the feeding ratio of the taurine to the magnesium oxide to be too high; compared with example 1, the mass of the filtrate I in comparative example 3 is increased greatly, and the concentrations of magnesium and taurine are greatly reduced, which greatly increases the difficulty and work of evaporation concentration in the subsequent steps and is unnecessary.
Test example 2
The test process comprises the following steps: respectively detecting the solid II and the filtrate II in the step (2); there are two methods for measuring the magnesium content, and generally, when the magnesium content is too low (the content is only a few thousandths), the ICP method is adopted to measure the magnesium content; generally, the magnesium content is measured by EDTA titration; example 1, comparative example 4, "solid II" the measurement of magnesium content was by the "ICP method", and the measurement of magnesium in the remaining samples was by the "titration method".
And (3) test results: as shown in table 2:
TABLE 2 test results
| Example 1 | Comparative example 4 | |
| Solid II mass (g) | 23 | 11 |
| Solid II magnesium content (%) | 0.10 | 0.10 |
| Solid II taurine content (%) | 93.9 | 93.9 |
| Filtrate II Mass (g) | 1460 | 1470 |
| Filtrate II magnesium content (%) | 1.74 | 1.74 |
| Filtrate II taurine content (%) | 18.59 | 19.32 |
| The molar ratio of taurine to magnesium in the filtrate II | 2.05 | 2.13 |
As can be seen from table 2, compared to example 1, comparative example 4 precipitated less free taurine in step 2, and thus the free taurine in "filtrate ii" was higher (from the molar ratio of taurine to magnesium in filtrate ii), indicating that the purity of magnesium taurate in "filtrate ii" in example 1 was higher, which is more favorable for subsequent separation and purification. Comparative example 5 in step (3), the temperature for evaporation concentration was 20 ℃; in comparative example 5, when concentration was carried out halfway up to step (3), the solution became turbid a lot because magnesium ions were hydrolyzed, so that relatively pure magnesium taurate could not be obtained in evaporative concentration.
From the above results, it is understood that the present application provides a method for synthesizing magnesium taurate, and the parameters in the preparation method, such as the mass ratio of water, taurine and magnesium oxide, the temperature for temperature reduction in step (2) only, and the temperature for evaporation and concentration in step (3) are limited, and experiments with the above parameters out of the range of the present application are carried out in the comparative example of the present application, and the desired effects of the present application cannot be achieved by verification.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (1)
1. The method for synthesizing the magnesium taurate is characterized by comprising the following steps of:
(1) Keeping the temperature of water at 65-75 ℃, adding taurine while stirring, and then adding a magnesium compound, wherein the mass ratio of the water to the taurine to the magnesium compound is as follows: water: taurine: stirring a magnesium compound =13 for 30-40 min to obtain a mixed solution a, cooling the mixed solution a to 4-6 ℃, and continuously stirring for 2-4 h to obtain a mixed solution B; the magnesium compound is magnesium oxide;
(2) Filtering or centrifuging the mixed solution B obtained in the step (1) to obtain a filtrate I and a solid I, cooling the obtained filtrate I to-1-3 ℃, and filtering or centrifuging to obtain a filtrate II and a solid II;
(3) Evaporating and concentrating the filtrate II obtained in the step (2) under a vacuum condition or a nitrogen charging condition to obtain a concentrated solution, wherein the mass ratio of the concentrated solution to the filtrate II is as follows: concentrating the solution: filtrate II = 35-45, the temperature of evaporation concentration is 1-3 ℃, stirring is continuously carried out for 2-4 h, and filtration or centrifugation is carried out to obtain filtrate III and solid III;
(4) And (4) washing the solid III obtained in the step (3), wherein the temperature of washing water is 0-1 ℃, and drying to obtain the magnesium taurate, wherein the drying temperature is 2-6 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110702332.4A CN113387847B (en) | 2021-06-23 | 2021-06-23 | Synthetic method of magnesium taurate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110702332.4A CN113387847B (en) | 2021-06-23 | 2021-06-23 | Synthetic method of magnesium taurate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113387847A CN113387847A (en) | 2021-09-14 |
| CN113387847B true CN113387847B (en) | 2022-11-22 |
Family
ID=77623758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110702332.4A Active CN113387847B (en) | 2021-06-23 | 2021-06-23 | Synthetic method of magnesium taurate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113387847B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1887862A (en) * | 2006-07-19 | 2007-01-03 | 江阴南极星生物制品有限公司 | Synthesis of magnesium taurylate |
| CN101693679A (en) * | 2009-09-23 | 2010-04-14 | 黄再新 | Method for synthesizing magnesium taurate |
| CN111960972A (en) * | 2020-08-28 | 2020-11-20 | 许昌远志生物科技有限公司 | Preparation process and application of taurine magnesium salt and taurine magnesium complex |
-
2021
- 2021-06-23 CN CN202110702332.4A patent/CN113387847B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1887862A (en) * | 2006-07-19 | 2007-01-03 | 江阴南极星生物制品有限公司 | Synthesis of magnesium taurylate |
| CN101693679A (en) * | 2009-09-23 | 2010-04-14 | 黄再新 | Method for synthesizing magnesium taurate |
| CN111960972A (en) * | 2020-08-28 | 2020-11-20 | 许昌远志生物科技有限公司 | Preparation process and application of taurine magnesium salt and taurine magnesium complex |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113387847A (en) | 2021-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106976849B (en) | Purification method of lithium bis (fluorosulfonyl) imide | |
| CN115259231B (en) | Method for removing calcium and magnesium impurities in manganese sulfate | |
| CN113387847B (en) | Synthetic method of magnesium taurate | |
| EP4137476B1 (en) | Method for preparing adamantyltrimethylammonium hydroxide, and aqueous quaternary ammonium base solution prepared thereby | |
| US11306158B1 (en) | Method for preparing high-purity sugammadex sodium | |
| CN109516487B (en) | Method for preparing calcium bicarbonate powder by solvent method | |
| NO176136B (en) | Process for the preparation of cyanamide | |
| CN115784875A (en) | Preparation process of bis (2-acetoxybenzoic acid) calcium urea | |
| CN107129446B (en) | Process for reducing sulfate ions in synthetic process of 2-acrylamido-2-methylpropanesulfonic acid | |
| CN111018744B (en) | Method for synthesizing acetamidine, acetamidine and application thereof, and vitamin B1 | |
| US3848063A (en) | Process for the manufacture of high-purity lithium hexafluoroarsenate | |
| CN114292203A (en) | Preparation method of DL-panthenol | |
| US3947496A (en) | Process for recovering glycine from sodium sulfate solutions | |
| JP2005029476A (en) | METHOD FOR PRODUCING tert-BUTYLACRYLAMIDE | |
| CN114763321B (en) | Ozone composition, preparation method thereof and method for preparing glyoxylic acid by reactive distillation | |
| CN113880066B (en) | Method for preparing lithium difluorophosphate by flow chemistry method | |
| CN114369074B (en) | Method for preparing L-calcium ascorbate byproduct L-ascorbic acid-2-phosphate | |
| CN113185464B (en) | Preparation method of zinc histidine | |
| CN111362820B (en) | Low-ammonia synthesis method of iminodisuccinate | |
| CN114195662B (en) | Method for synthesizing high-content calcium disodium edetate | |
| CN112375031B (en) | Preparation method of cilnidipine | |
| US20240092639A1 (en) | Method for recovering lithium bis(fluorosulfonyl)imide | |
| JPH101452A (en) | Production of calcium pyruvate and its hydrate | |
| CN118324663A (en) | Efficient synthesis process for preparing methyl cyanamide from cyanamide | |
| US20230406809A1 (en) | Method of preparing heterogeneous linear carbonate using amine-based compound catalyst |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |